Skip to main content
. Author manuscript; available in PMC: 2023 Feb 8.
Published in final edited form as: JAMA Netw Open. 2022 Mar 1;5(3):e222037. doi: 10.1001/jamanetworkopen.2022.2037

Table.

Baseline Characteristics ofthe Study Participants According to Living Arrangement Status (Living Alone vs Living With Others) and Treatment Assignment (Intensive vs Standard Blood Pressure Control)Among Blackand Non-BlackIndividualsa

Variables Treatment assignment of Black participants, No (%) Treatment assignment of non-Black participants, No (%)a
Living alone (N = 1001) Living with others (N = 1792) Living alone (N = 1713) Living with others (N = 4836)
Intensive (N = 493) Standard (N = 508) Intensive (N = 881) Standard (N = 911) Intensive (N = 860) Standard (N = 853) Intensive (N = 2435) Standard (N = 2401)
Sex
 Female 255 (51.7) 257 (50.6) 372 (42.2) 382 (41.9) 414 (48.1) 389 (45.6) 636 (26.1) 615 (25.6)
 Male 238 (48.3) 251 (49.4) 509 (57.8) 529 (58.1) 446 (51.9) 464 (54.4) 1799 (73.9) 1786 (74.4)
Age, mean (SD), y 65.3 (9.1) 65.4 (9.4) 63.5 (8.8) 63.7 (8.7) 71.7 (9.2) 71.9 (9.3) 68.7 (8.9) 68.5 (9.1)
Education status
 Less than college 384 (77.9) 386 (76.0) 683 (77.5) 678 (74.4) 469 (54.5) 470 (55.1) 1295 (53.2) 1244 (51.8)
 College or above 109 (22.1) 109 (24.0) 198 (22.5) 233 (25.6) 391 (45.5) 383 (44.9) 1140 (46.8) 1157 (48.2)
Insurance
 Private 83 (16.9) 97 (19.2) 245 (27.8) 226 (24.8) 128 (14.9) 114 (13.4) 583 (24.0) 603 (25.1)
 Public 319 (65.0) 323 (64.0) 463 (52.6) 514 (56.5) 673 (78.3) 678 (79.7) 1685 (69.2) 1624 (67.7)
 Uninsured 89 (18.1) 85 (16.8) 172 (19.6) 170 (18.7) 59 (6.9) 59 (6.9) 166 (6.8) 173 (7.2)
Smoking status
 Never 205 (42.1) 216 (43.1) 396 (45.5) 402 (44.5) 379 (44.6) 394 (46.9) 1073 (44.5) 1056 (44.2)
 Current 118 (24.2) 119 (23.8) 206 (23.7) 196 (21.7) 91 (10.7) 77 (9.2) 224 (9.3) 209 (8.8)
 Former 164 (33.7) 166 (33.1) 268 (30.8) 305 (33.8) 379 (44.6) 370 (44.0) 1117 (46.3) 1123 (47.0)
 Alcohol intake 271 (55.2) 297 (58.8) 475 (54.3) 500 (55.2) 592 (69.0) 573 (69.5) 1641 (67.6) 1645 (68.6)
Baseline blood pressure, mean (SD), mm Hg
 Systolic 140.0 (16.7) 139.4 (16.5) 139.2 (16.8) 140.4 (15.4) 139.9 (15.4) 141.5 (16.2) 139.7 (15.3) 138.8 (14.8)
 Diastolic 80.6 (12.8) 80.4 (12.4) 81.5 (12.4) 81.8 (12.2) 75.6 (11.3) 76.2 (12.0) 77.5 (11.4) 76.8 (11.4)
Clinical cardiovascular disease 50 (10.1) 57 (11.2) 85 (9.7) 87 (9.6) 139 (16.2) 143 (16.8) 465 (19.1) 433 (18.0)
Subclinical cardiovascular disease 46 (9.3) 37 (7.3) 75 (8.5) 82 (9.0) 60 (7.0) 66 (7.7) 199 (8.2) 208 (8.7)
Statin use 162 (33.2) 181 (35.9) 268 (30.5) 332 (36.6) 377 (44.0) 380 (44.9) 1171 (48.4) 1182 (49.6)
Aspirin use 203 (41.2) 215 (42.4) 359 (40.9) 372 (40.9) 499 (58.1) 413 (48.5) 1345 (55.3) 1348 (56.3)
No.of antihypertensive medications
 0 39 (7.9) 30 (5.9) 69 (7.8) 68 (7.5) 77 (9.0) 116 (13.6) 238 (9.8) 229 (9.5)
 1 131 (26.6) 157 (30.9) 236 (26.8) 258 (28.3) 289 (33.6) 259 (30.4) 810 (33.3) 799 (33.3)
 2 163 (33.1) 188 (37.0) 323 (36.7) 301 (33.0) 291 (33.8) 292 (34.2) 832 (34.2) 800 (33.3)
 ≥3 160 (32.4) 133 (26.2) 253 (28.7) 284 (31.2) 203 (23.6) 186 (21.8) 555 (22.8) 573 (23.9)
10-y Framingham cardiovascular disease risk %, median (IQR) 14.8 (11.3) 14.7 (12.6) 14.9 (11.3) 15.2 (12.3) 18.0 (15.9) 19.1 (15.1) 19.3 (13.4) 19.1 (13.9)
a

Non-Black individuals indicatethosewho identified asAlaskan Native, American Indian, Asian, Native Hawaiian, Pacific Islander, White, orotherduringtheSystolicBlood Pressure InterventionTrial.